Looking back and looking forward, building dreams | Shenzhen Cell Valley 2023 corporate events
quotation
At the beginning of the New Year, everything changes
Review 2023
Shenzhen Cell Valley
Gather strength and forge ahead
Use the power of science and technology to write a chapter of industry innovation
01/January
Shenzhen Cell Valley's one-stop cell and gene therapy CRO/CDMO service platform - South China Cell Factory project was approved as a major public service platform in Shenzhen and received tens of millions of project funding support
The project is the only cell and gene therapy CRO/CDMO service platform among the 13 major public service platforms established in Shenzhen, taking a solid first step towards 2023.
02 / February
1. Shenzhen Cell Valley won the title of "Top Ten Innovation Platform" in Pingshan District in 2022
As a strategic emerging industry and future industry, cell and gene therapy is an important starting point for Pingshan District to achieve innovative and high quality, and realize innovation to empower the future.
2. Chairman Shi Yuanyuan was invited to give an academic lecture at the Institute of Biophysics, Chinese Academy of Sciences
Chairman Professor Shi Yuanyuan held an academic lecture with the title of "Current Situation and Prospect of Cell Therapy". Academicians of Chinese Academy of Sciences, Academicians of Academy of Sciences of Developing countries, Academician Wang Zhizhen, researcher of Institute of Biophysics of Chinese Academy of Sciences, and more than 100 teachers and students listened to the scene and spoke about the development of cell and gene therapy industry and Shenzhen Cell Valley, gradually opening the publicity channels of universities.
03 / March
In-depth exchanges with leading enterprises in the industry, broaden market channels, and achieve resource complementarity
Shenzhen Cell Valley team to Shanghai Enkai Cell Technology Co., LTD., Yao Ming Junuo, North Hengsheng chemical and other industry leading pharmaceutical companies exchange visits, introduce Shenzhen Cell Valley core technology advantage - retroviral vector, gradually open the market visibility, expand the market channels, and explore the cooperation model of strong joint, to achieve complementary advantages of resources.
04 / April
1, wholly-owned subsidiary Junhou biological virus vector CDMO platform expansion project has been completed, service capabilities further upgraded!
After the Junhou Bio expansion project was put into operation, A total of 7,000 square meters of B+A, C+A and other viral vector and cell product workshops and GLP laboratories in line with international GMP standards were built with Shenzhen Cell Valley. Zhongshan and Shenzhen realized the interaction of cell therapy industry, and gradually realized the effective layout of the whole industrial chain from carrier to cell to clinical. Create a one-stop cell and gene therapy CRO/CDMO service platform to promote Shenzhen Cell Valley to a higher level!
2.Chairman Shi Yuanyuan served as the first president of the Medical and Health Branch of Shenzhen Youth Science Association
The medical and health industry is an important field involving people's health and happiness. Through cross-industry activities, Shenzhen Cell Valley promotes the exchange and cooperation of scientific and technological innovation, realizes knowledge and information sharing and cross-field resource integration, forms the linkage of production, university and research, and promotes the transformation of results.
3.Chairman Shi Yuanyuan and Chief scientist Wang Jianxun were selected as expert members of China Food and Drug Enterprise Quality and Safety Promotion Association
The list of 43 expert members published on the website of the China Food and Drug Promotion Association includes academicians, professors, doctors and entrepreneurs from government agencies, scientific research institutes, medical institutions, technology companies and other food and drug fields across the country, of which 7 are experts from Shenzhen. Gradually expand its involvement in various fields, actively cooperate and exchange with all walks of life, share industry development information, and promote the development of cell and gene therapy.
05 / May
1. Shenzhen Cell Valley and Shenzhen Inuo Immunology Co., Ltd. jointly developed the first TCR-T cell product based on retroviral vector in China
The two parties signed a strategic cooperation agreement, and jointly declared topics, and launched comprehensive cooperation in product development, clinical research and IND declaration in the future. The two sides make good use of their respective advantages, integrate resources, open up the whole industrial chain from research and development to production to approval, and promote the continuous innovation and rapid development of domestic cell products based on retroviral vectors!
2.Shenzhen Cell Valley into the storage of science and technology small and medium-sized enterprises
Science and technology smes are the key objects encouraged and supported by the state, the key basic force of the national science and technology innovation system, and an important engine to promote national economic development. Shenzhen Cell Valley has always been committed to continuously promoting the research and development and innovation of cell and gene therapy technology, constantly improving its core competitiveness, and contributing to the development of national science and technology.
3.Shenzhen Cell Valley was approved as Shenzhen Pingshan District college student practice base
Shenzhen Cell Valley focuses on cultivating high-quality professionals needed by the cell and gene therapy industry for the country, providing full-cycle services for enterprises and scientific research institutions in the field of cell and gene therapy, and opening up cooperation channels with more universities through the internship base of college students, jointly cultivating professional and technical talents, and contributing to the development of the country.
06 / June
1.Shenzhen Cell Valley and cell industry key common technology National Engineering Research Center major cooperation signing ceremony was held
Relying on the common technology research platform of viral vectors, the two sides have carried out close and comprehensive cooperation in the field of cell therapy professional training, the establishment of an automated cell product preparation platform based on retroviruses, and the promotion of IT+BT digital intelligent production line of cell products.
2. Shenzhen Cell Valley was approved as the supporting unit of Shenzhen Medical Research Special Fun
In order to implement the task of the construction of the demonstration zone, the Shenzhen Municipal government set up the "Shenzhen Medical Research Special Fund", Shenzhen Cell Valley passed the expert review, approved as the Shenzhen medical research special fund supporting unit, will make continuous efforts in the future Shenzhen medical research special fund application work, and create new achievements!
07 / July
1. Leaders of Beijing Daxing District, Beijing Chaoyang District and Hunan Provincial People's Congress visited Shenzhen Cell Valley
Shenzhen Cell Valley as a cell and gene therapy CRO&CDMO enterprise, with the cutting-edge biotechnology - cell therapy, the core competitive advantage - retroviral vector, by the attention of provincial government leaders, government leaders through research and investigation to understand the cell and gene therapy industry, and the frontier technology of Shenzhen Cell Valley expressed high appreciation.
08/ August
1. Luo Wenzhi, director of the Standing Committee of Shenzhen Municipal People's Congress, led a team to investigate Shenzhen Cell Valley
Luo Wenzhi, director of the Standing Committee of Shenzhen Municipal People's Congress, led a team to Shenzhen Cell Valley to visit and investigate, and Shenzhen Cell Valley is committed to solving the industrial production of the "stuck neck" technology - retroviral vector in CGT drugs, as well as providing pharmaceutical companies with the whole industry chain and full cycle one-stop service of "R&D - production - declaration - talent training" of cell original drugs. It has fully affirmed the development of cell and gene therapy.
2. Shenzhen Cell Valley was appointed as the vice president unit of the national first-level industry association, and Professor Shi Yuanyuan appointed Professor Wang Jianxun as the vice president and chief scientist of the Cell Medicine Branch of China Food and Drug Promotion Association as the deputy chairman of the Expert Committee
Chairman Professor Shi Yuanyuan was invited to attend and preside over the founding meeting of the Cell Medicine Branch of China Food and Drug Enterprise Quality and Safety Promotion Association and the high-quality Development Forum of Cell medicine, and jointly explore new treatment ideas for cancer treatment, cancer treatment and other fields with experts and scholars in the industry, contributing to the improvement of treatment effects and the improvement of patients' quality of life.
09 / September
Shenzhen Cell Valley approved 2023 innovative small and medium-sized enterprises
After Shenzhen Cell Valley won the title of science and technology smes in May, another small and medium-sized enterprise honor, Shenzhen Cell Valley with innovative technology, team strength, industry-leading products and services, successfully passed the selection and approval of innovative smes.
10/October
1.Shenzhen Cell Valley and Fosun Kat Biotechnology Co., Ltd. launched a comprehensive strategic cooperation
Shenzhen Cell Valley and industry leading enterprise Fosun Kat Biotechnology Co., Ltd. launched a comprehensive strategic cooperation, the two sides around the new pipeline research and development based on retroviral vectors, IIT, IND declaration, talent joint training, reduce CAR T production costs and other aspects of cooperation, to promote the whole industry chain of cell therapy high-quality rapid development, Build an ecological chain of leading cell therapy enterprises in Shenzhen.
2. Shenzhen Cell Valley won the bid for the procurement project of "GMP grade CAR T cell preparation" from Huazhong University of Science and Technology Union Shenzhen Hospital
Based on this project, the two sides will jointly carry out clinical research and clinical application of CAR-T cell therapy in different types of blood diseases, improve the therapeutic effect, and promote cell therapy products to the clinic.
3.Chairman Shi Yuanyuan and chief scientist Wang Jianxun were selected as expert members of the Shenzhen Light Industry Engineering Senior Title Review Committee (personalized cell)
After Chairman Shi Yuanyuan and chief scientist Wang Jianxun successively won the honorary title of expert committee in 2023, they also won the expert Committee of Shenzhen Light Industry Engineering Senior professional Title uation Committee (Personalized cell), which is the daily work department of Cell Technology National Laboratory as the professional technical Qualification uation Committee of Shenzhen City. Under the guidance of Shenzhen Human Resources and Social Security Bureau and other superior departments, organize experts and carry out independent professional title uation work in related fields.
11/November
1. Shenzhen Cell Valley was elected as the vice chairman unit of Shenzhen Biomedical Production and Education Alliance
Shenzhen Cell Valley has reached a deep cooperation with Shenzhen Vocational and Technical University, using the school-enterprise cooperation model to jointly build a multi-dimensional, all-round and deep-level talent education and training platform, from the compilation of teaching materials, theoretical teaching to practice to enhance the cooperation and interaction of the whole process system, to help the applied talent training of innovative technology and scientific and technological innovation.
2. Shenzhen Cell Valley won the third prize of the "Science and Technology Innovation Future Industry Bay Area" China Innovation and Entrepreneurship Association Innovation and Entrepreneurship Competition
On behalf of Shenzhen Cell Valley, Sun Rui, Director of the Marketing Department, participated in the project of "Establishment of Industrial production System of Cellular Drugs based on Retrovirus vector". Industry experts of the project comprehensively scored and strictly selected a total of 540 entrepreneurial projects from five dimensions: technology and product, business model and implementation plan, industry and market, comprehensive ability of core team and financial analysis. In the end, 32 outstanding innovative and entrepreneurial projects stood out and successfully qualified for the final, of which only 10 were biomedical & Agricultural technology/food technology projects.
3. Shenzhen Cell Valley and its wholly-owned subsidiary Junhou Biology have both filed through the biosafety P2 laboratory
The standardization and perfection of Shenzhen Cell Valley and its wholly-owned subsidiary Junhou Biology in biosafety management have been affirmed, and provide a more solid guarantee for the company's scientific research and innovation, while helping the continuous upgrading and optimization of products and services.
4. Shenzhen Cell Valley won the "Excellent Enterprise Award" in the 12th China Innovation and Entrepreneurship Competitio
Shenzhen Cell Valley won another excellent achievement, following the successful entry into the 12th China Innovation and Entrepreneurship Competition in September 2023, after fierce competition, stood out from many participants in the national competition, and won the Excellent Enterprise Award. Only six of the 20 finalists in Shenzhen won awards.
5. Shenzhen Cell Valley achieved a major breakthrough in CAR-NK preparation process
NK cells were transduced by retrovirus vector produced by PackRV-SS system unique to Shenzhen Cell Valley. The transduction efficiency was stable above 60%, and the positive rate remained stable. Moreover, CAR-NK cells proliferated up to 10,000 times within 30 days of culture after transduction.
12/December
1. Shenzhen Cell Valley was approved as the innovation platform construction project of Shenzhen High-tech Zone Development Special Plan and received government funding support
Shenzhen Cell Valley has been awarded a municipal platform, after the preliminary review of data, site inspection, re-uation and other layers of assessment, Shenzhen Cell Valley declared the results industrialization base innovation platform construction project "Cell therapy product development and industrialization talent training base construction project based on retroviral vector technology" successfully passed the review and received the project approval notice.
2. Chairman Shi Yuanyuan was hired as the first think tank expert of "Shenzhen Biomedicine Industry Innovation Chain Committee of the Communist Party of China"
The first municipal biomedicine industry innovation Chain Party Committee in Guangdong-Hong Kong-Macao Greater Bay Area - "Shenzhen Biomedicine Industry Innovation Chain Committee" was officially established in Pingshan District, Shenzhen. The first think tank experts are composed of 11 influential experts in the field of biomedicine industry innovation from Shenzhen universities, hospitals, scientific research institutions and enterprises. Jointly contribute to the collaborative innovation and development of industry, education, research, medicine, resources, government and management in the Greater Bay Area.
3. the Cell Therapy International Summit Forum was successfully held, and Shenzhen Cell Valley · South China Cell Factory was officially put into operation
With the care and support of many leaders and people from all walks of life, Shenzhen Cell Valley Biomedicine Co., Ltd. held the launch ceremony of "Shenzhen Cell Valley • South China Cell Factory" and the "International Summit Forum on Cell Therapy" in Pingshan District, Shenzhen. The summit, sponsored by the Cell Medicine Branch of China Association for Food and Drug Promotion and jointly hosted by Peking University Shenzhen Hospital and Shenzhen Cell Valley Biomedicine Co., LTD., invited Academician Wang Zhizhen, Vice Chairman of the 11th National Committee of the Chinese People's Political Consultative Conference, and other leading experts and scholars in the industry to gather at the event to discuss the trend and future of cell therapy.
4. Shenzhen Cell Valley was approved as a high-growth enterprise of "Jurong Leading Talents" (Class D) in the biomedical field of Pingshan District in 2023
As an important member of the biomedicine strategic emerging industry and the cell and gene future industry in Shenzhen's "20+8" industrial cluster, Shenzhen Cell Valley will continue to exert its technological advantages and innovation capabilities, increase R&D investment, accelerate the transformation of innovation achievements, and contribute to the upgrading and development of the biomedicine industry in Pingshan District.
Wave goodbye to the striving 2023
Stride forward Hua Zhang initial exhibition 2024
Shenzhen Cell Valley
New Year, new journey, new dream
The spirit of daring to be the first
Ride on the wind and row harder
Write a new chapter in Cell Valley
